Kansen HM, et al. - This encompassed the assessment of the consequence of immunomodulators on the formation of antibodies to infliximab (ATI) in paediatric patients with Crohn's disease (CD) and the association of ATI and loss of response. A link was brought to light between combination therapy with a notable reduction of antibody formation and prolonged effectivity in children with CD, compared to infliximab (IFX) monotherapy. It was reported that early combined immunosuppression (ECI) for at least 12 months, followed by IFX monotherapy, could be an equally effective alternative to continuous combined immunosuppression (CCI).